Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

• Author(s): Antunes, Liliana ; Rojas-Castro, Madelyn ; Lozano, Marcos ; Martínez-Baz, Iván ; Leroux-Roels, Isabel ; Borg, Maria-Louise ; Oroszi, Beatrix ; Fitzgerald, Margaret ; Dürrwald, Ralf ; Jancoriene, Ligita ; Machado, Ausenda ; Petrović, Goranka ; Lazar, Mihaela ; Součková, Lenka ; Bacci, Sabrina ; Howard, Jennifer ; Verdasca, Nuno ; Basile, Luca ; Castilla, Jesús ; Ternest, Silke ; Džiugytė, Aušra ; Túri, Gergő ; Duffy, Roisin ; Hackmann, Carolin ; Kuliese, Monika ; Gomez, Verónica ; Makarić, Zvjezdana Lovrić ; Marin, Alexandru ; Husa, Petr ; Nicolay, Nathalie ; Rose, Angela M.C. ; VEBIS SARI VE network team
• Date: 2025
• Persistent ID: http://hdl.handle.net/10400.18/10518
• Origin: Repositório Científico do Instituto Nacional de Saúde
• Subject(s): Case–control Study; Elderly; Severe Acute Respiratory Infections (SARI); Test‐negative Design; Vaccine Effectiveness; VEBIS-LOT1; Cuidados de Saúde; Infecções Respiratórias; Europe
• Document Type: Journal article
• Language: English
• Contributor(s): Repositório Científico do Instituto Nacional de Saúde

Description

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.